secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTEGRATED BIOPHARMA INC (INBP)
CIK:        0001016504
Form:       8-K
Filed at:   2026-09-25T21:05:32+00:00
Accession:  0001437749-26-031247
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Integrated BioPharma FY2026 revenue falls 19.3% to $43.9M; swings to $2.8M net loss from $0.8M income
--------------------------------------------------------------------------------

- Q4 revenue $9.8M vs $14.2M a year earlier, down $4.4M or 31.0%; Q4 operating loss $0.9M vs $0.6M operating income.
- FY2026 operating loss ~$2.7M vs FY2025 operating income $2.0M; Q4 gross profit collapsed to $28K from $1.47M.
- FY net loss ~$2.8M (-$0.09/share) vs FY2025 net income ~$0.8M ($0.03/share); Q4 net loss ~$1.4M (-$0.04 vs -$0.01).
- Co-CEOs Riva Sheppard and Christina Kay: two largest Contract Manufacturing customers were ~90% of FY2026 revenue, up from 84% in FY2025.
- FY2026 income tax expense of $0.3M recorded despite pre-tax loss of $2.6M; weighted average shares 31.06M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1016504/000143774926031247/0001437749-26-031247-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1016504/000143774926031247/inbp20260925_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-031247

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer